GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DuChemBio Co Ltd (XKRX:176750) » Definitions » EBIT

DuChemBio Co (XKRX:176750) EBIT : ₩5,415 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is DuChemBio Co EBIT?

DuChemBio Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was ₩5,415 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩5,415 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. DuChemBio Co's annualized ROC % for the quarter that ended in Dec. 2023 was 9.40%. DuChemBio Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 25.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. DuChemBio Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.61%.

DuChemBio Co EBIT Historical Data

The historical data trend for DuChemBio Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DuChemBio Co EBIT Chart

DuChemBio Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -9,799.31 -5,845.19 2,166.95 -1,186.32 5,415.39

DuChemBio Co Semi-Annual Data
Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT Get a 7-Day Free Trial -9,799.31 -5,845.19 2,166.95 -1,186.32 5,415.39

Competitive Comparison of DuChemBio Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, DuChemBio Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DuChemBio Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DuChemBio Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where DuChemBio Co's EV-to-EBIT falls into.


DuChemBio Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩5,415 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DuChemBio Co  (XKRX:176750) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

DuChemBio Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=5256.033 * ( 1 - 1.26% )/( (58746.723 + 51687.943)/ 2 )
=5189.8069842/55217.333
=9.40 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=51351.399 - 4460.774 - ( 2605.304 - max(0, 24187.452 - 12331.354+2605.304))
=58746.723

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=49276.827 - 4278.134 - ( 1980.767 - max(0, 19357.391 - 12668.141+1980.767))
=51687.943

Note: The Operating Income data used here is one times the annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

DuChemBio Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=5415.389/( ( (17977.619 + max(3852.343, 0)) + (16185.586 + max(5282.636, 0)) )/ 2 )
=5415.389/( ( 21829.962 + 21468.222 )/ 2 )
=5415.389/21649.092
=25.01 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8032.406 + 771.025 + 87.219999999999) - (4460.774 + 0 + 577.534)
=3852.343

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8329.809 + 1307.234 + 277.325) - (4278.134 + 0 + 353.598)
=5282.636

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

DuChemBio Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=5415.389/207409.615
=2.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DuChemBio Co EBIT Related Terms

Thank you for viewing the detailed overview of DuChemBio Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

DuChemBio Co (XKRX:176750) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DuChemBio Co Ltd (XKRX:176750) » Definitions » EBIT
Comparable Companies
XKRX:002620 XKRX:214390 XKRX:023910 XKRX:082800 XKRX:002390 XKRX:061250 XKRX:006620 XKRX:003120 XKRX:002210 XKRX:293780 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
Daegu 47, Jinyang Building, 4th floor, Chungjeong-ro 2, Gyeonggi, Seoul, KOR, 190-3
Website
http://www.duchembio.com
DuChemBio Co Ltd is engaged in manufacturing and sale of radiopharmaceuticals and radioactive medicines. It also imports and sells medical equipment related to nuclear medicines.

DuChemBio Co (XKRX:176750) Headlines

No Headlines